FLAG Therapeutics

Executive Summary

FLAG Therapeutics is a near-term clinical stage biotechnology company focused on developing novel small molecule therapeutics for difficult-to-treat cancers. Its lead candidate, FLAG-003, is being developed for Diffuse Intrinsic Pontine Glioma (DIPG), a rare and fatal pediatric brain tumor, and glioblastoma multiforme (GBM). The company is on track to initiate Phase 1 clinical trials in early 2026 in children with DIPG, leveraging a mechanism of action that targets tumor-specific vulnerabilities. With no approved therapies for DIPG and limited options for GBM, FLAG-003 addresses significant unmet medical needs. The company is privately held and based in Durham, North Carolina.

Upcoming Catalysts (preview)

• Q1 2026Phase 1 Clinical Trial Initiation for FLAG-003 in DIPG80% success
• H1 2026Presentation of Preclinical Data at a Major Medical Conference90% success
• 2026FDA Orphan Drug Designation Update or Additional Regulatory Milestone70% success